EGFR and neoplasm: The expression levels of miRNAs upon EGFR-TKI treatment have been reported to differ between drug-resistant and sensitive tumor cells and undergo differential regulation; therefore, miRNA-based therapies may be a possible strategy to reverse drug resistance and present a targeted therapy option for the adjuvant treatment of cancer.